Drug Trial Radar · NCT07951021
Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) Plus Low-Dose Lenvatinib, Iparomlimab and Tuvonralimab, and SBRT in Hepatocellular Carcinoma With Macrovascular Tumor Thrombus
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Nov 15, 2028
Study completion Nov 20, 2028
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hepatocellular carcinoma (HCC) with macrovascular tumor thrombus carries a poor prognosis, and systemic therapy alone provides limited benefit in this population. This single-center, single-arm, phase 2 trial evaluates the efficacy and safety of a regimen combining chemotherapy-minimized, blank microsphere-based transarterial chemoembolization (BMS-TACE), low-dose lenvatinib, the anti-PD-1/CTLA-4 bispecific antibody iparomlimab and tuvonralimab, and stereotactic body radiotherapy (SBRT). In BMS-TACE, blank microspheres are the principal embolic agent and chemotherapy is used only as an adjunct at a fixed, minimal dose (doxorubicin 10 mg and lobaplatin 10 mg), in order to limit chemotherapy-related liver injury and systemic toxicity and to allow repeated embolization in patients with limited hepatic reserve. Forty-two participants with BCLC stage C HCC and tumor thrombus in the main portal vein or superior mesenteric vein (Vp3/Vp4), hepatic vein, or inferior vena cava, without extrahepatic metastases, will be enrolled. The primary endpoint is progression-free survival assessed by blinded independent central review using mRECIST.
Conditions
- Hepatocellular Carcinoma
- Portal Vein Tumor Thrombus
- Hepatic Vein Tumor Thrombus
- Inferior Vena Cava Tumor Thrombus
Interventions
BMS-TACEProcedure
Visceral angiography of the celiac trunk, superior mesenteric artery and, as indicated, collateral arteries maps the arterial supply of the tumor and tumor thrombus and identifies arteriovenous shunting. A 2.8F microcatheter is placed super-selectively into tumor-feeding arteries by coaxial technique. A fixed, minimal-dose chemoemulsion (doxorubicin 10 mg and lobaplatin 10 mg in about 5 mL lipiodol) is injected slowly; chemotherapy may be omitted in later sessions according to tumor response, leaving blank-microsphere embolization alone. Blank microspheres are then delivered in ascending size order (40-120, 100-300, then 300-500 or 500-700 microns). The endpoint is contrast stasis over 3-5 cardiac cycles plus angiography 5-10 minutes later confirming loss of more than 90% of tumor staining. Imaging is repeated 4-6 weeks after each session; retreatment follows protocol-defined criteria. Participants generally receive two complete sessions.
LenvatinibDrug
Lenvatinib 8 mg orally once daily for body weight 60 kg or above, or 4 mg orally once daily for body weight below 60 kg, started 3 to 7 days after the first BMS-TACE. Lenvatinib is withheld on the day of each BMS-TACE or SBRT and resumed 3 to 5 days afterwards provided the Child-Pugh score is 5 to 8; cumulative interruption does not exceed 3 weeks. Treatment continues until disease progression, unacceptable toxicity, or withdrawal of consent.
Iparomlimab and TuvonralimabDrug
Iparomlimab and tuvonralimab (QL1706), an anti-PD-1/anti-CTLA-4 bispecific antibody combination, 5 mg/kg intravenously every 3 weeks, infused over at least 30 minutes. Dosing starts 3 to 7 days after the first BMS-TACE and is separated from any BMS-TACE by at least 3 days. Treatment continues until disease progression or unacceptable toxicity. Immune-related adverse events are managed according to protocol-defined rules, including dose interruption, corticosteroid therapy and permanent discontinuation criteria.
Stereotactic Body RadiotherapyRadiation
Stereotactic body radiotherapy directed primarily at the macrovascular tumor thrombus. Simulation uses vacuum-bag or thermoplastic immobilization with 4D-CT or gated CT (slice thickness 3 mm or less). The prescription is 30 to 50 Gy in 5 to 10 fractions, individualized by tumor size and location, normal liver volume and Child-Pugh score: 40-50 Gy in 5 fractions when normal liver volume is 700 mL or more with Child-Pugh 5-6; 35-40 Gy in 5-8 fractions when normal liver volume is 500-700 mL or Child-Pugh is 7; and 30-40 Gy in 10 fractions when the target is within 1 cm of stomach, duodenum or colon. The prescription covers at least 95% of the planning target volume. Daily kV cone-beam CT image guidance is used with setup correction to within 3 mm. A minimum interval of 14 days separates SBRT and BMS-TACE in either direction.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) by blinded independent central review (BICR) using mRECISTTime frame: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months (14-month accrual plus 12 months of follow-up after the last participant is enrolled)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.